Mannatech (MTEX) Competitors $9.85 -0.86 (-7.99%) Closing price 04/17/2025 02:18 PM EasternExtended Trading$9.36 -0.49 (-4.98%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. SLN, MGNX, JMAC, BDTX, ENTX, VIGL, AVTE, VTYX, IMAB, and ACOGShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Silence Therapeutics (SLN), MacroGenics (MGNX), Maxpro Capital Acquisition (JMAC), Black Diamond Therapeutics (BDTX), Entera Bio (ENTX), Vigil Neuroscience (VIGL), Aerovate Therapeutics (AVTE), Ventyx Biosciences (VTYX), I-Mab (IMAB), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Silence Therapeutics MacroGenics Maxpro Capital Acquisition Black Diamond Therapeutics Entera Bio Vigil Neuroscience Aerovate Therapeutics Ventyx Biosciences I-Mab Alpha Cognition Mannatech (NASDAQ:MTEX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends. Which has more risk and volatility, MTEX or SLN? Mannatech has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Do insiders & institutionals believe in MTEX or SLN? 13.0% of Mannatech shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MTEX or SLN more profitable? Mannatech has a net margin of -1.26% compared to Silence Therapeutics' net margin of -342.00%. Mannatech's return on equity of -15.62% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-1.26% -15.62% -3.76% Silence Therapeutics -342.00%-62.81%-33.89% Does the MarketBeat Community prefer MTEX or SLN? Mannatech received 283 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 79.63% of users gave Silence Therapeutics an outperform vote while only 77.43% of users gave Mannatech an outperform vote. CompanyUnderperformOutperformMannatechOutperform Votes32677.43% Underperform Votes9522.57% Silence TherapeuticsOutperform Votes4379.63% Underperform Votes1120.37% Do analysts recommend MTEX or SLN? Silence Therapeutics has a consensus target price of $40.67, suggesting a potential upside of 1,195.12%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has stronger earnings & valuation, MTEX or SLN? Mannatech has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.16-$2.24M$1.337.40Silence Therapeutics$43.26M2.17-$53.82M-$0.95-3.31 Does the media prefer MTEX or SLN? In the previous week, Mannatech had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Mannatech and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.67 beat Mannatech's score of 0.25 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMannatech and Silence Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.72M$1.18B$5.30B$7.34BDividend YieldN/AN/A5.45%4.30%P/E Ratio-12.1510.0421.8617.80Price / Sales0.169.44380.6697.70Price / CashN/A10.4038.2634.64Price / Book1.751.216.453.98Net Income-$2.24M-$56.07M$3.22B$247.81M1 Month Performance0.36%-8.04%-9.76%-7.85%1 Year Performance18.14%-40.40%11.48%1.60% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech1.2811 of 5 stars$9.85-8.0%N/A+20.1%$18.72M$117.87M-12.15250Analyst ForecastGap DownSLNSilence Therapeutics1.997 of 5 stars$2.71+5.4%$40.67+1,400.6%-85.7%$81.11M$43.26M-1.73100News CoveragePositive NewsGap UpMGNXMacroGenics3.7507 of 5 stars$1.27-1.6%$7.38+480.7%-92.2%$80.12M$148.34M-0.80430News CoverageGap UpJMACMaxpro Capital AcquisitionN/A$5.95-2.5%N/A+1,011.3%$79.83MN/A0.002,021Gap DownBDTXBlack Diamond Therapeutics3.1445 of 5 stars$1.40+0.7%$14.60+942.9%-72.8%$79.33MN/A-1.0590Short Interest ↑Gap DownENTXEntera Bio1.8154 of 5 stars$1.74+3.0%$10.00+474.7%-20.1%$79.03M$181,000.00-6.6920VIGLVigil Neuroscience2.7082 of 5 stars$1.60+7.4%$16.25+915.6%-37.8%$78.60MN/A-0.7840Positive NewsGap UpAVTEAerovate Therapeutics0.8069 of 5 stars$2.71+1.9%$2.25-17.0%-87.3%$78.55MN/A-0.9120Positive NewsVTYXVentyx Biosciences1.4551 of 5 stars$1.10+13.6%$10.00+809.1%-75.4%$78.24MN/A-0.4730IMABI-Mab3.1031 of 5 stars$0.96+42.8%$5.50+475.5%-52.8%$77.89M$3.27M0.00380Short Interest ↓Gap UpHigh Trading VolumeACOGAlpha Cognition1.6368 of 5 stars$4.83+10.3%$20.00+314.1%N/A$77.38MN/A-1.89N/APositive News Related Companies and Tools Related Companies SLN Alternatives MGNX Alternatives JMAC Alternatives BDTX Alternatives ENTX Alternatives VIGL Alternatives AVTE Alternatives VTYX Alternatives IMAB Alternatives ACOG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
